UBS Revises Jazz Pharmaceuticals Outlook, Citing Strong Core Business and Promising Oncology Drug

Deep News05-19 21:20

UBS Group adjusted its rating on Jazz Pharmaceuticals PLC shares on Monday, turning bullish on the stock due to the resilience of its core operations and the commercial promise of a new cancer treatment.

The bank upgraded Jazz Pharmaceuticals from "Neutral" to "Buy" and significantly raised its price target to $307. This target suggests a potential upside of over 33% from Monday's closing price. Analyst Ashwani Verma noted in a report on Tuesday that the company's drug Ziihera, used to treat gallbladder cancer, is nearing fast-track approval ahead of a regulatory deadline on August 25. He also highlighted that the company's other business segments are performing well.

Verma stated, "We believe the stability of the sleep disorder drug franchise appears manageable in the face of pricing pressures and potential competitive entry from Orexin in the second half of 2026, and this is overshadowed by the new growth opportunity represented by Ziihera. Additionally, Modeyso, a drug for treating a type of brain cancer, is expected to generate significant sales in the next one to two years."

Since the beginning of 2026, shares of Jazz Pharmaceuticals have risen by 35%, and over the past year, they have doubled in value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116466839?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116466839","market":"nz","top_or_hot":-1,"title":"UBS Revises Jazz Pharmaceuticals Outlook, Citing Strong Core Business and Promising Oncology Drug","media":"Deep News","content":"<p>UBS Group adjusted its rating on Jazz Pharmaceuticals PLC shares on Monday, turning bullish on the stock due to the resilience of its core operations and the commercial promise of a new cancer treatment.</p>\n<p>The bank upgraded Jazz Pharmaceuticals from \"Neutral\" to \"Buy\" and significantly raised its price target to $307. This target suggests a potential upside of over 33% from Monday's closing price. Analyst Ashwani Verma noted in a report on Tuesday that the company's drug Ziihera, used to treat gallbladder cancer, is nearing fast-track approval ahead of a regulatory deadline on August 25. He also highlighted that the company's other business segments are performing well.</p>\n<p>Verma stated, \"We believe the stability of the sleep disorder drug franchise appears manageable in the face of pricing pressures and potential competitive entry from Orexin in the second half of 2026, and this is overshadowed by the new growth opportunity represented by Ziihera. Additionally, Modeyso, a drug for treating a type of brain cancer, is expected to generate significant sales in the next one to two years.\"</p>\n<p>Since the beginning of 2026, shares of Jazz Pharmaceuticals have risen by 35%, and over the past year, they have doubled in value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Revises Jazz Pharmaceuticals Outlook, Citing Strong Core Business and Promising Oncology Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Revises Jazz Pharmaceuticals Outlook, Citing Strong Core Business and Promising Oncology Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-05-19 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS Group adjusted its rating on Jazz Pharmaceuticals PLC shares on Monday, turning bullish on the stock due to the resilience of its core operations and the commercial promise of a new cancer treatment.</p>\n<p>The bank upgraded Jazz Pharmaceuticals from \"Neutral\" to \"Buy\" and significantly raised its price target to $307. This target suggests a potential upside of over 33% from Monday's closing price. Analyst Ashwani Verma noted in a report on Tuesday that the company's drug Ziihera, used to treat gallbladder cancer, is nearing fast-track approval ahead of a regulatory deadline on August 25. He also highlighted that the company's other business segments are performing well.</p>\n<p>Verma stated, \"We believe the stability of the sleep disorder drug franchise appears manageable in the face of pricing pressures and potential competitive entry from Orexin in the second half of 2026, and this is overshadowed by the new growth opportunity represented by Ziihera. Additionally, Modeyso, a drug for treating a type of brain cancer, is expected to generate significant sales in the next one to two years.\"</p>\n<p>Since the beginning of 2026, shares of Jazz Pharmaceuticals have risen by 35%, and over the past year, they have doubled in value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823416689.USD","symbol_name":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"","article_id":"1116466839","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116466839","pubTimestamp":1779196857,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"UBS Group adjusted its rating on Jazz Pharmaceuticals PLC shares on Monday, turning bullish on the stock due to the resilience of its core operations and the commercial promise of a new cancer...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","BK4532":"文艺复兴科技持仓","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","JAZZ":"爵士制药","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC"},"translate_title":"瑞银修正Jazz Pharmaceuticals展望，理由是核心业务强劲且肿瘤药物前景广阔","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"UBS Group adjusted its rating on Jazz Pharmaceuticals PLC shares on Monday, turning bullish on the stock due to the resilience of its core operations and the commercial promise of a new cancer treatment.\nThe bank upgraded Jazz Pharmaceuticals from \"Neutral\" to \"Buy\" and significantly raised its price target to $307. This target suggests a potential upside of over 33% from Monday's closing price. Analyst Ashwani Verma noted in a report on Tuesday that the company's drug Ziihera, used to treat gallbladder cancer, is nearing fast-track approval ahead of a regulatory deadline on August 25. He also highlighted that the company's other business segments are performing well.\nVerma stated, \"We believe the stability of the sleep disorder drug franchise appears manageable in the face of pricing pressures and potential competitive entry from Orexin in the second half of 2026, and this is overshadowed by the new growth opportunity represented by Ziihera. Additionally, Modeyso, a drug for treating a type of brain cancer, is expected to generate significant sales in the next one to two years.\"\nSince the beginning of 2026, shares of Jazz Pharmaceuticals have risen by 35%, and over the past year, they have doubled in value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116466839","isCrawlerRequest":true}